biotech news today glp-1 Lilly is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Korea's First GLP-1 Obesity Drug

I was a little skeptical

Nausea occurs in approximately 15-20% of patients and represents the most common side effect, typically emerging during dose escalation and often diminishing over several weeks as tolerance develops

Medical oversight A key point regarding GLP-1 medications, including in a microdosing context, is that they are prescription drugs designed for specific medical conditions (like type 2 diabetes and obesity) and require professional guidance

In 3-MCC, the body uses up a lot of carnitine to try and grab the toxic byproducts (like C5-OH ) and carry them out through the urine [3] [4]

If you ever decide to move on, you take it all with you, no strings